A Single and Multiple Dosing Study Targeting Biparatopic Antibody CD38 in Healthy Volunteers

Healthy Volunteer Clinical Trial

Official title:

A Phase 1, Double-blind, Single- and Multiple-ascending Dose Escalation Study of TNB-738, a Biparatopic Antibody Targeting CD38 in Healthy Volunteers

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT05215912
• Other study ID #: TNB-738
• Status: Completed
• Phase: Phase 1
• Start date: April 21, 2022
• Est. completion date: July 11, 2023

Study information

• Verified date: February 2023
• Source: Ancora Biotech LLC
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This is a Phase 1, Double blind, Single ascending and Multiple ascending dose (SAD and MAD) escalation study in Healthy Volunteers.

Description:

TNB-738 is a fully human bispecific antibody used to inhibit human CD38 enzyme.

The study will consist of 2 arms (A and B). The SAD arm (Arm A) of the study consists of sequential single dose escalation cohorts, whereas the MAD portion (Arm B) of the study consists of sequential dose escalation cohorts receiving study drug once every 4 weeks for 3 doses. In both Arm A and Arm B, subjects will be randomized to receive either TNB-738 or matching placebo.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 31
• Est. completion date: July 11, 2023
• Est. primary completion date: May 4, 2023
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 18 Years to 75 Years

Eligibility

Inclusion Criteria:

1. Healthy male or female

2. Age 18 - 75

3. Body mass index (BMI) ranging between 18 and 35 kg/m2, inclusive

4. Female subjects of child-bearing potential must agree to use one of the study-approved effective contraceptive methods for the duration of the study

5. Male subjects must practice true abstinence or agree to use a condom while participating in the study through End of study (EOS)

6. If female, a negative serum pregnancy test at Screening and urinary pregnancy test at Day -1 is required

7. Able to read, understand, and provide signed informed consent

8. Able to communicate adequately with the investigator and to comply with the requirements for the entire study.

Exclusion Criteria:

1. Subject has any significant medical condition that would prevent the subject from participating in the study.

2. Subject is pregnant or breastfeeding.

3. Subject is currently receiving treatment with a biologic agent.

4. Subject has a history of anaphylactic reactions to biologic agents.

5. Subject has been dosed with another investigational drug study within 60 days prior to study drug administration.

6. Subject has current or recent (within 4 weeks prior to screening) signs or symptoms of infection that require antibiotic administration.

7. Subject has evidence of COVID-19 infection and/or subject is deemed at risk for the coronavirus disease in the opinion of the investigator or the subject has participated in another clinical study involving treatment(s), which may increase such risk.

8. Subject has used any prescription (excluding hormonal birth control) drugs within 14 days or illicit drugs within 30 days, or 5 half-lives (whichever is longer), prior to study drug administration.

9. Subject has a positive urine drug test or alcohol breath test at screening.

10. Subject has donated or lost more than 1 unit of blood (500 mL) within 60 days or more than 1 unit of serum within 7 days before the study drug administration.

11. Subject is HIV, HBV, or HCV positive.

12. Subject has received a live virus vaccine within 4 weeks of dosing

Related Conditions & MeSH terms

• Healthy Volunteer

Intervention

Drug:
• TNB-738
TNB-738 is an investigation drug. Other: Matching placebo
• TNB-738
TNB-738 is an investigation drug. Other: Matching placebo

Locations

Country	Name	City	State
Australia	Q-Pharm Pty Ltd	Herston	Queensland

Sponsors (2)

Lead Sponsor	Collaborator
TeneoFour Inc.	Novotech (Australia) Pty Limited

Country where clinical trial is conducted

Australia, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Safety and tolerability of TNB-738 by the incidence of treatment emergent adverse events in Single Ascending group. Adverse Events will be graded according to the NCI-CTCAE, version 5.0		13 weeks
Primary	Safety and tolerability of TNB-738 by the incidence of treatment emergent adverse events in Multiple Ascending group. Adverse Events will be graded according to the NCI-CTCAE, version 5.0		21 weeks
Primary	To investigate the Cmax (maximum Serum concentration) of TNB-738 following Single Ascending Dose.		13 weeks
Primary	To investigate the Cmax (Maximum Serum concentration) of TNB-738 following Multiple Ascending Dose		21 weeks
Primary	Tmax (time for maximum serum concentration) for Single Ascending Dose		13 weeks
Primary	Tmax (time for maximum serum concentration) for Multiple Ascending Dose		21 weeks
Primary	Terminal elimination half-life (t1/2) for Single Ascending Dose		13 weeks
Primary	Terminal elimination half-life (t1/2) for Multiple Ascending Dose		21 weeks
Secondary	Anti drug antibodies (ADA) as a measurement of immunogenicity following Single Ascending Dose of TNB-738		13 weeks
Secondary	Anti drug antibodies (ADA) as a measurement of immunogenicity following Multiple Ascending Dose of TNB-738		21 weeks
Secondary	To determine CD38 enzyme activity following Single Ascending Dose		13 weeks
Secondary	To determine CD38 enzyme activity following Multiple Ascending Dose		21 weeks